SEC Form 4 · accession 0001192482-18-000109
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Berelowitz
Director
Period of report
Mar 9, 2018
Accepted (ET)
Mar 13, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 9, 2018 | M | 7,500 | $2.47 | A | 7,500 | D | |
| Common StockF1 | Mar 9, 2018 | S | 7,500 | $10.4462 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.47 | Mar 9, 2018 | M | 7,500 | D | — | Dec 17, 2024 | Common Stock | 7,500 | 14,500 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.411 to $10.5053, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
- F2The option vested on December 17, 2015.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney